Tirzepatide, with its dual GLP-1 and GIP action, seems to show the highest weight loss potential, though it is still under evaluation
WEGOVY- semaglutide tablet, DailyMed (2026) Lillys oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity, Lilly (2025) Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes, a randomized clinical trial, JAMA Network Open (2023) Pfizer provides update on oral GLP-1 receptor agonist danuglipron, Pfizer (2025) Oral semaglutide, Clinical Diabetes (2020) Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet (2023) A review of current guidelines for the treatment of obesity, American Journal of Managed Care (2022) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
: , , , , , , , , , , , , , , , ,
While patients may wonder about tirzepatide and yeast infections, current evidence shows no direct causal link between this medication and fungal infections
Semaglutide increases insulin secretion and reduces glucagon release
Cesare Patrone, Karolinska Institutet (KI), Sweden Updates Copyright 2020 Kim, Kim and Song
